The Future of Vaccinology
Wednesday, March 30, 2022, 9:00 AM - Thursday, March 31, 2022, 5:30 PM EDT
New York City
Presented By
Microbiology and Infectious Diseases Discussion Group
The New York Academy of Sciences
Historically, vaccine development has been a slow process, though new scientific discoveries and technologies in the last quarter century accelerated advances in virology and vaccinology. More recently, a possible paradigm shift has emerged — the race to develop COVID-19 vaccines demonstrated massive achievements in speed and efficacy of new vaccine development using both old and novel vaccine platforms.
To better understand what we can learn from recent successes in vaccine development and deployment, this two-day conference will convene leaders in vaccinology, virology, immunology, biotechnology, microbiology, systems biology, and health policy. Session topics include a look back at advances in vaccine development, updates from present-day vaccinology, a discussion on how vaccine development can be strengthened based on COVID-19 vaccine learnings, pharma company pipeline updates, next generation vaccine adjuvants, improving immune measures, and more.
Scientific Organizing Committee
Pfizer
Novavax
Viomme
Human Vaccines Project
New York Academy of Sciences
Keynote Speakers
Bill and Melinda Gates Research Institute
University of Pennsylvania
Speakers
Pfizer
Janssen Vaccines & Prevention B.V.
GlaxoSmithKline
University of Oxford
Bill and Melinda Gates Research Institute
University of Pennsylvania
Inovio
Novavax
National Institute for Allergy and Infectious Diseases, NIH
IAVI
CEPI
Stanford University
Valneva
Harvard University
BIOASTER
Viome
Johns Hopkins University
Stanford University
GlaxoSmithKline
Sanofi Pasteur
Wednesday
March 30, 2022
Check in and Breakfast
WELCOME REMARKS
Speaker
KEYNOTE SPEAKER
Speaker
WHERE WE WERE
SESSION I: A Look Back at Advances in Vaccine Development
KEYNOTE ADDRESS: Perseverance and Progress: Vaccinology in the Last 50 years
Speaker
Lessons from COVID-19: Comparative Advantages and Weaknesses of mRNA, Adenoviral Vector, and Protein–Adjuvant Vaccine Platforms
Speaker
Break
WHERE WE ARE
SESSION II: Present-Day Vaccinology
Panel Discussion: How Can Vaccine Development Be Strengthened Based on COVID-19 Vaccine Learnings
Speakers
Lingering Hurdles — The Big 3: HIV, TB, and Malaria
Speaker
Lunch and Poster Session
SESSION II: Present-Day Vaccinology (Continued)
Protecting the Vulnerable: Newborns, the Elderly, the Immunocompromised, and Individuals in Low-Resource Settings
Speaker
Vaccine Durability
Speaker
SESSION III: Short Talks Selected from Submitted Abstracts
Speaker to Be Selected
Speaker to Be Selected
Break
SESSION IV: Pipeline Updates
Late Stage Pipleine of Vaccines for Infectious Diseases
Speaker
The Late Stage Pipeline of Vaccines for Infectious Diseases
Speaker
Sanofi’s Late Stage Pipeline of Vaccines for Infectious Diseases
Speaker
Late-Stage Vaccine Developments for Infectious Diseases
Speaker
Closing Remarks, Day 1
Speaker
End of Day 1
Thursday
March 31, 2022
Check in and Breakfast
WELCOME REMARKS
Speaker
WHERE ARE WE GOING
SESSION V: Vaccines for Chronic Infectious Diseases
The Pathway and Lessons Learned from the Shingles Vaccine
Speaker
Chronic Viral Infectious Diseases
Speaker
Chronic Bacterial Infectious Diseases, Learnings from the VLA15 Multivalent Recombinant Protein Vaccine for Lyme Disease
Speaker
Break
SESSION VI: Next Generation Vaccine Adjuvants
Adjuvanted Vaccines Targeted to Vulnerable Populations
Speaker
Next Generation Vaccine Adjuvants
Speaker
Lunch and Poster Session
SESSION VII: Immune Response to Vaccination
The Impact of the Microbiome on Immunity
Speaker
Biological Sex and Age Affect Immunity Following Vaccination
Speaker
SESSION VIII: Making Immune Measures More Efficient, Agile, and Meaningful
Immune Monitoring: Vaccination Indicators of Immunological Health and Responsiveness
Speaker
Systems Biology in Vaccine Design and Development
Speaker
Break
SESSION VIII: Continued
Advances in Artificial Intelligence Tools to Speed Vaccine Development
Speaker
SESSION IX: Closing Keynote
What the Future Holds for Vaccine Development
Speaker
Closing Remarks
Speaker